OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
27
Results
Show all
Save search
Copy query
Show results for
Unknown
(27)
Publication Date
Release Date
2023
(6)
2022
(5)
2021
(4)
2018
(3)
2025
(2)
2024
(2)
2014
(2)
2020
(1)
2017
(1)
2016
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Not available
S-EPMC7845943
|
biostudies-literature
Cite
Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.
Not available
S-EPMC10958653
|
biostudies-literature
Cite
Concordance Between Tissue <i>ALK</i> Detection by Immunohistochemistry and Plasma <i>ALK</i> Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced <i>ALK</i>-Positive NSCLC.
Not available
S-EPMC9218556
|
biostudies-literature
Cite
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.
Not available
S-EPMC4340255
|
biostudies-literature
Cite
High-dose alectinib for
RET
fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Not available
S-EPMC10883190
|
biostudies-literature
Cite
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Not available
S-EPMC9499854
|
biostudies-literature
Cite
SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy.
Not available
S-EPMC12133423
|
biostudies-literature
Cite
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Not available
S-EPMC9365376
|
biostudies-literature
Cite
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Not available
S-EPMC11271410
|
biostudies-literature
Cite
Rapid real-world data analysis of patients with cancer, with and without COVID-19, across distinct health systems.
Not available
S-EPMC8209944
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets